Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers
© 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd..
The susceptibility of cells to DNA damage and their DNA repair ability are crucial for cancer therapy. Homologous recombination is one of the major repairing mechanisms for DNA double-strand breaks. Approximately half of ovarian cancer (OvCa) cells harbor homologous recombination deficiency (HRD). Considering that HRD is a major hallmark of OvCas, scholars proposed HRD scoring to evaluate the HRD degree and guide the choice of therapeutic strategies for OvCas. In the last decade, synthetic lethal strategy by targeting poly (ADP-ribose) polymerase (PARP) in HR-deficient OvCas has attracted considerable attention in view of its favorable clinical effort. We therefore suggested that the uses of other DNA damage/repair-targeted drugs in HR-deficient OvCas might also offer better clinical outcome. Here, we reviewed the current small molecule compounds that targeted DNA damage/repair pathways and discussed the HRD scoring system to guide their clinical uses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Fundamental & clinical pharmacology - 37(2023), 2 vom: 26. Apr., Seite 194-214 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Chunxiu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA repair |
|---|
| Anmerkungen: |
Date Completed 06.03.2023 Date Revised 06.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/fcp.12834 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346464595 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346464595 | ||
| 003 | DE-627 | ||
| 005 | 20231226031525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/fcp.12834 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346464595 | ||
| 035 | |a (NLM)36130021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Chunxiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2023 | ||
| 500 | |a Date Revised 06.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd. | ||
| 520 | |a The susceptibility of cells to DNA damage and their DNA repair ability are crucial for cancer therapy. Homologous recombination is one of the major repairing mechanisms for DNA double-strand breaks. Approximately half of ovarian cancer (OvCa) cells harbor homologous recombination deficiency (HRD). Considering that HRD is a major hallmark of OvCas, scholars proposed HRD scoring to evaluate the HRD degree and guide the choice of therapeutic strategies for OvCas. In the last decade, synthetic lethal strategy by targeting poly (ADP-ribose) polymerase (PARP) in HR-deficient OvCas has attracted considerable attention in view of its favorable clinical effort. We therefore suggested that the uses of other DNA damage/repair-targeted drugs in HR-deficient OvCas might also offer better clinical outcome. Here, we reviewed the current small molecule compounds that targeted DNA damage/repair pathways and discussed the HRD scoring system to guide their clinical uses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a DNA repair | |
| 650 | 4 | |a PAPR inhibitors | |
| 650 | 4 | |a epigenetic modifications | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a small molecular drugs | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 700 | 1 | |a Liu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Chaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Lipeng |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Dongsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Ziwen |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Zhigang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hanqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Fundamental & clinical pharmacology |d 1990 |g 37(2023), 2 vom: 26. Apr., Seite 194-214 |w (DE-627)NLM012737992 |x 1472-8206 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:2 |g day:26 |g month:04 |g pages:194-214 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/fcp.12834 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 2 |b 26 |c 04 |h 194-214 | ||